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S U M M A R Y
Objectives: To characterize invasive Haemophilus inﬂuenzae and to examine the population at risk for
invasive H. inﬂuenzae disease in British Columbia, Canada, 2008–2009.
Methods: H. inﬂuenzae recovered from individual patients were characterized by serotyping, biotyping,
multilocus sequence typing (MLST), and antibiotic susceptibility testing. Age information was recorded
from specimen requisition forms.
Results: Of the 98 cases, 66%were caused by non-typeable strains, followed by serotypes b (12%), a (10%),
f (10%), and e (1%). Cases caused by serotypes b and f and non-typeable strainsweremainly in adults over
18 years of age, while cases due to serotype a were mainly in children under the age of 2 years. Different
sequence types were found in encapsulated strains according to their serotypes, and non-typeable
strains had their own unique sequence types. No capsule switching was documented. Antibiotic
resistance was common among non-typeable strains, with 31% identiﬁed as genotypic b-lactamase-
negative ampicillin-resistant (BLNAR) strains.
Conclusion: InvasiveH. inﬂuenzae disease in a population vaccinated against Hibwas age-dependent and
involved both non-typeable and encapsulated strains. Adults were susceptible to invasive diseases due
to non-typeable and serotype b and f strains, while in children, most diseases were due to serotype a
bacteria.
Crown Copyright  2010 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Haemophilus inﬂuenzae is a strict human respiratory tract
pathogen that can cause a spectrum ofmild (otitismedia, sinusitis)
to severe (meningitis, epiglottitis, cellulitis, septicemia) disease.
Six different serotypes have been identiﬁed based on the
serological speciﬁcities of their polysaccharide capsules,1 with
capsular serotype b as the predominant strain associated with
invasiveH. inﬂuenzae disease. Strainswithout capsules are referred
to as non-typeable.
Before the introduction of vaccines against H. inﬂuenzae,
invasive H. inﬂuenzae disease was mainly a childhood disease,
with most cases found in children under the age of 10 years and
caused mostly by serotype b organisms.2,3 Vaccination against H.
inﬂuenzae serotype b (Hib) was introduced in the 1980s, ﬁrst with
the plain polysaccharide vaccine, and soon followed by conjugated
vaccines in the early 1990s, which induce T-cell-mediated long-
term immunity and are immunogenic when given to infants.4* Corresponding author. Tel.: +1 204 789 6020; fax: +1 204 789 2130.
E-mail address: Raymond.tsang@phac-aspc.gc.ca (R. Tsang).
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doi:10.1016/j.ijid.2010.10.005Dramatic reductions in invasive H. inﬂuenzae disease were
reported shortly after countries introduced Hib conjugate vaccines
into their routine childhood immunization programs. In the USA,
elimination of Hib disease was considered a possible goal.5 In
Canada, a historic low in the number of invasive Hib disease was
recorded as early as 2000 (with only four cases found by a network
of 12 major pediatric centers across the country), eight to nine
years after the Hib conjugate vaccine was introduced.6
Before Hib conjugate vaccines were widely used, non-Hib H.
inﬂuenzae (either non-encapsulated strains or other serotypes)
were not regarded as signiﬁcant causes of invasive disease.2,3,7 In
theory, vaccines that target only one serotype may drive the
organism to either switch and/or replace their capsules with non-
vaccine capsular types or shed their capsule altogether to become
resistant to the vaccine.8–10 Capsule switching involves strains
with capsule types included in the vaccine acquiring capsule
synthesis genes from strains with capsule types not included in the
vaccine, to become resistant to the vaccine while still retaining
their original virulence characters. Capsule replacement occurs
when strains with capsule types not included in the vaccine
emerge and replace strains with capsule types included in the
vaccine to cause disease.9 Indeed, non-Hib H. inﬂuenzae, whichLtd on behalf of International Society for Infectious Diseases. All rights reserved.
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invasive disease.11–14
In the past, surveillance of invasive H. inﬂuenzae disease had
been restricted to monitoring only Hib cases. In the last several
years, the National Microbiology Laboratory (NML) has begun to
monitor invasive H. inﬂuenzae disease by characterizing strains
recovered from invasive disease cases, regardless of their capsule
status or capsular type. However, this work has been restricted to
only one region of the country, namely Manitoba and North-
western Ontario.12,13 A recent study in the province of Ontario
has conﬁrmed that strain replacement is happening in invasive H.
inﬂuenzae disease.14 Canada has a relatively small population of
about 34 million in relation to its territorial size of about 9.9
million square kilometers or 3.8 million square miles. Previous
studies on H. inﬂuenzae have mainly focused on isolates
recovered from two neighboring provinces of Manitoba and
Ontario, situated in the centre to eastern part of the country,
respectively. In order to gain a wider perspective of this invasive
bacterial disease and to study the evolving nature of the
causative agent, we extended our study to British Columbia,
which is located in the most western part of the country, about
3000 km or 2000 miles from Ontario. In this study, the British
Columbia Center for Disease Control (BCCDC) Public Health
Microbiology and Reference Laboratory in collaboration with the
NML examined invasive disease cases and characterized the H.
inﬂuenzae isolates obtained in the last 2 years. The objectives of
this study were to examine (1) the biology of the current invasive
H. inﬂuenzae strains, and (2) the population currently at risk for
invasive disease, after more than 15 years of Hib conjugate
vaccine usage in this country.
2. Materials and methods
2.1. Bacterial isolates
From January 1, 2008 to December 31, 2009, there were 98
strains of invasive H. inﬂuenzae isolates submitted to the British
Columbia Center for Disease Control’s Public Health Microbiology
and Reference Laboratory for serotyping as part of the routine
practice. All isolates were from individual cases with invasive
disease as determined by the submitting laboratory, and duplicate
isolates from the same patient were excluded from this study. One
patient had two separate episodes of infection due to a non-
typeable strain that occurred several months apart, and isolates
from each infection have been included. Identities of all isolates
were conﬁrmed by standard biochemical tests15 and 16S rRNA
sequencing.16 Biotypes were assigned according to Kilian’s
biotyping scheme based on three biochemical reactions: urease,
indole production, and ornithine decarboxylase.17
2.2. Serotyping
The serotypes were determined by slide agglutination test
using antisera against all six serotypes purchased from commercial
sources (Difco, Oakville, Ontario, Canada; Denka Seiken, Tokyo,
Japan). Serotyping by PCR detection of the serotype-speciﬁc genes
and the capsule transport, bexA, genewas carried out using primers
described by Falla et al.18
2.3. Multilocus sequence typing
Multilocus sequence typing (MLST) was carried out by PCR
ampliﬁcation of seven housekeeping genes (adk, atpG, frdB, fucK,
mdh, pgi and recA) according to themethod previously described,19
and the assignment of sequence types (STs) was done using the H.
inﬂuenzae MLST website (http://haemophilus.mlst.net/).2.4. Antibiotic resistance and b-lactamase production
b-Lactamase production was detected using DrySlide Nitroce-
ﬁn (BBL, Becton Dickinson, Oakville, Ontario, Canada). Disk
diffusion testing was carried out as described by the Clinical
and Laboratory Standards Institute (CLSI).20 The following anti-
biotics were tested: ampicillin, amoxicillin–clavulanic acid,
cefaclor, ceftriaxone, chloramphenicol, ciproﬂoxacin, clarithromy-
cin, levoﬂoxacin, moxiﬂoxacin, trimethoprim–sulfamethoxazole,
and tetracycline (Oxoid, Nepean, Ontario, Canada). In addition, a 2-
mg ampicillin disk was also used to detect b-lactamase-negative
isolates showing reduced susceptibility to ampicillin.21 b-Lacta-
mase-negative ampicillin-resistant (BLNAR) H. inﬂuenzae strain
ATCC 49247 was used as a control in each experiment.
2.5. Determination of BLNAR genotype by ftsI gene sequencing
PCR ampliﬁcation of the ftsI gene, which encodes penicillin-
binding protein 3 (PBP3), was carried out on all strains. Previously
described primers and conditions were used to amplify approxi-
mately 1 kb of the 1.8-kb ftsI gene.22 The resulting PCR products
were puriﬁed using the QIAquick PCR puriﬁcation kit and
sequenced. Results were compared to a previously published
GenBank sequence of a b-lactamase-negative ampicillin-suscep-
tible (BLNAS) H. inﬂuenzae strain to determine any amino acid
substitutions (GenBank accession number L42023).23 Strains with
ftsI gene mutations that led to amino acid substitutions in their
PBP3 were classiﬁed into groups according to the nomenclature
used by Ubukata et al.22 and Dabernat et al.24
3. Results
3.1. Invasive H. inﬂuenzae cases in British Columbia, 2008–2009
There were 53 individual case isolates in 2008 and 45 in 2009.
Age information for the 98 cases is presented in Figure 1A. Overall,
79% of the cases (n = 77) occurred in individuals over the age of 10
years, and only 21% of the cases (n = 21) were in children under 11
years of age; 17% (n = 17) were in children aged 2 years or younger.
When cases were broken down into the responsible serotypes,
signiﬁcant differences were found (Figure 1B). For cases due to
Hib, 25% (3/12 cases) were found in children aged 2 years or below
and 75% (9/12 cases) were found in adults aged 21 years or above.
In contrast, 80% (8/10 cases) of the serotype a cases were in
children under 2 years, and there were only two adult cases, in the
age group ranges of 51–60 years and 61–70 years. Similar to Hib,
most of the cases due to non-typeable H. inﬂuenzae were in adults
over the age of 20 years (54/65 cases; 83%); 9% (6/65 cases) of the
non-typeable cases were in children aged under 2 years and
another 5% of the caseswere in children aged 3–10 years. Unique to
the serotype f cases was that with the exception of one child (7
years old), only adults were affected.
Most of the 98 invasive isolates (n = 80; 82%) were recovered
from blood cultures. There were only 10 cases with H. inﬂuenzae
recovered from the cerebrospinal ﬂuid, and in three of these 10
cases, the isolates were also found in blood cultures. The remaining
invasive case isolates were recovered from various body sites, as
shown in Table 1.
3.2. Serotypes and biotypes of invasive H. inﬂuenzae in British
Columbia
Non-typeable strains accounted for most of the cases (n = 65;
66%), followed by serotype b (n = 12; 12%) and serotypes a (n = 10;
10%) and f (n = 10; 10%); the remaining casewas due to a serotype e
strain (Table 1).
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Figure 1. (A) Distribution of the 98 invasive Haemophilus inﬂuenzae isolates from British Columbia by patient age range. (B) Serotype distribution by age range for the 98
invasive Haemophilus inﬂuenzae isolates from British Columbia.
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serotype e isolate, 10 of the serotype b isolates, and nine serotype f
isolates were all identiﬁed as biotype I. Two serotype b and one
serotype f were found to be biotype II. Biotypes I, II, III, IV, V, VI, and
VII were found among the non-typeable isolates, with biotype II
being the most common biotype found (58%).
3.3. Clonal analysis of invasive H. inﬂuenzae from British Columbia
None of the 33 serotypeable isolates were found to have a ST
identical or related to theSTs foundamongthenon-typeable isolates
(datanot shown).Eachserotypewasmadeupof isolateswithunique
STs and the STs observedwere not found inmore than one serotype
(Table2).Of the12STs identiﬁed in the33serotypeable isolates, only
two identical alleles were found among isolates belonging toTable 1
Serotypes and sources of isolation of 98 invasive Haemophilus inﬂuenzae isolates
collected in British Columbia, 2008–2009
Source Serotype
a b e f Non-typeable
Blood 5 11 1 8 55
CSF 3 1 2 1
Blood and CSF 2 1
Lung 2
Brain 1
Meninges 1
Pelvic abscess 1
Eye socket 1
Pleural ﬂuid 1
Tissue: product of conception 1
Total 10 12 1 10 65
CSF, cerebrospinal ﬂuid.different serotypes. One serotype b isolate (ST-53) shared an
identical frdB allele with serotype a isolates belonging to three
different STs. Similarly, a single serotype f isolate (ST-16)was found
to have an atpG allele identical to that in the single serotype e isolate
(ST-66). The non-typeable isolates were divided into 40 unique STs
and showed a high degree of diversity in their seven housekeeping
gene allelic proﬁles (Figure 2).
3.4. Antibiotic susceptibility of invasive H. inﬂuenzae in British
Columbia
The antibiotic resistance proﬁles, production of b-lactamase,
and ftsI genemutations for the 98 invasiveH. inﬂuenzae isolates are
shown in Table 3. There was no ampicillin resistance due to b-
lactamase production seen among the 33 serotypeable isolates.
The only observed resistance among the serotypeable isolates was
two isolates showing resistance to trimethoprim–sulfamethoxa-
zole (one serotype b and one serotype f).
On the other hand, resistance to antibioticswas commonly found
among the non-typeable isolates. Thirteen of the 65 (20%) non-
typeable isolates were found to produce b-lactamase and were
resistant to ampicillin. In addition, 20 (31%) of the non-typeable
isolates contained signiﬁcantmutations in their ftsI genes that led to
amino acid substitutions occurring around the serine–serine–
asparagine (SSN) and lysine–threonine–glycine (KTG) motifs of
theirpenicillin-bindingprotein.22Mutationsnear the conservedSSN
and KTG regions were associated with decreased afﬁnity to
ampicillin; these mutations have been reported in known BLNAR
strains.22,24 Based on their ftsI gene sequences, 13 of the 20 non-
typeable isolates were classiﬁed as group IIb, four as group IId, and
one each as group I, group IIa, and group III. The amino acid
substitutions found among these 20 non-typeable isolates are
shown in Table 4.
Table 2
Allele proﬁle of housekeeping genes and sequence types as determined by multilocus sequence typing of serotypeable strains of invasive Haemophilus inﬂuenzae in British
Columbia, 2008–2009
Serotype No. of isolates Housekeeping gene allele number Sequence type
adk atpG frdB fucK mdh pgi recA
a 5 13 16 5 18 3 11 36 576
3 13 16 5 18 3 11 7 56
2 13 16 5 2 3 11 7 23
b 8 42 14 4 5 4 7 8 231
1 10 14 4 5 4 7 8 6
1 10 14 4 5 85 7 8 190
1 10 14 5 7 4 7 8 53
1 28 14 4 3 4 3 8 157
e 1 18 6 3 11 10 28 12 66
f 8 22 19 11 11 22 19 15 124
1 22 4 11 11 22 19 15 598
1 22 6 11 12 1 18 15 16
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have resistance tomultiple antibiotics (Table 3). Half (10/20) of the
genotypic BLNAR strains showed some degree of resistance to
ampicillin, e.g., resistance to the 2mg ampicillin disk and/or
intermediate to the 2 and 10 mg ampicillin disk. Three of the 13
non-typeable b-lactamase producing isolates had similar signiﬁ-
cant ftsI mutations and were therefore regarded as genotypic b-
lactamase-positive amoxicillin–clavulanic acid-resistant (BLPACR)
isolates.
4. Discussion
Although several prior publications have documented changes
in the epidemiology of invasive H. inﬂuenzae disease in the USA,
Canada, and Europe,11,12,25 few have provided details on the
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one ST (ST-190) was also found among the ﬁve Hib isolates
analyzed in Manitoba.26 Of the 17 Hib isolates typed in these two
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were found with 15 different alleles detected in the seven
housekeeping genes analyzed. The most varied housekeeping
gene was adk (four alleles), followed by fucK (three alleles), and
frdB, mdh, and pgi (each with two different alleles). No variations
were found in the atpG or recA genes.
In British Columbia, ST-576was themost common ST identiﬁed
in serotype a isolates (5/10 isolates), while in Manitoba, most
serotype a isolates (35/36 isolates) were typed as ST-23.26 ST-576
and ST-23 are highly related, with six of their seven housekeeping
gene alleles being identical. The degree of heterogeneity among theresults for 65 invasive non-typeable Haemophilus inﬂuenzae strains from British
f non-identical alleles between sequence types (STs)) are listed between each node
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Table 3
Antibiotic resistance proﬁles and amino acid substitutions in penicillin-binding protein 3 (PBP3) determined by ftsI gene sequencing in invasive Haemophilus inﬂuenzae from
British Columbia, 2008–2009
Serotype No. of isolates b-Lactamase production Antibiotic resistance proﬁlea PBP3 mutations
a 10  Susceptible to all No
b 1  Cec I No
1  Sxt R No
10  Susceptible to all No
e 1  Susceptible to all No
f 1  Sxt R No
9  Susceptible to all No
nt 5 + Amp R No
1 + Amp R, Cec I No
2 + Amp R, Clr I No
1 + Amp R, Sxt R No
1 + Amp R, Amc R No
nt 4  Sxt R No
28  Susceptible to all No
nt BLPACR genotype 1 + Amp R Yes
1 + Amp R, Clr I Yes
1 + Amp R, Chl R, Sxt R, Tet R Yes
nt BLNAR genotype 2  Amp I (2mg) Yes
4  Amp I (2 and 10mg) Yes
1  Amp R (2mg), Amp I (10mg) Yes
1  Amp R (2mg), Amp I (10mg), Cec I Yes
1  Amp I (2mg), Cec R, Sxt R Yes
1  Amp R, Amc R Yes
1  Cec R, Clr R Yes
5  Sxt R Yes
4  Susceptible to all Yes
nt, non-typeable; BLPACR, b-lactamase-positive amoxicillin–clavulanic acid-resistant; BLNAR, b-lactamase-negative ampicillin-resistant; R, resistant; I, intermediate; Amc,
amoxicillin–clavulanic acid; Amp, ampicillin; Cec, cefaclor; Chl, chloramphenicol; Clr, clarithromycin; Sxt, trimethoprim–sulfamethoxazole; Tet, tetracycline.
a Determined by disk diffusion according to Clinical and Laboratory Standards Institute (CLSI) guidelines.
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found among the Hib isolates. Variations in serotype a isolates
were only found in two housekeeping genes: recA (three alleles)
and fucK (two alleles), with the rest showing complete identity
between the 46 isolates studied. Even less variation was found
among the serotype f isolates in these two provinces: ST-124 was
the most common ST in British Columbia and was the only ST
found in the ﬁve serotype f isolates in Manitoba.
Our results from studies of Hib in British Columbia and
Manitoba appear to conﬁrm an earlier report of increased genetic
diversity of Hib in the post-Hib vaccination era.27 In contrast, the
clonal nature of serotype f isolates recovered in two different
provinces in Canada also support the clonal relationship of invasive
serotype f isolates recovered from Denmark and the USA.28
Serotype a H. inﬂuenzae infections have been frequently found
in aboriginal populations in both the USA29,30 and Canada.13,31
However, detailed genetic comparisons of strains recovered from
different localities have not been carried out, and its evolution in
response to Hib vaccine pressure is important to follow, as some
regard serotype a strains to be similar to Hib in terms of their
pathogenic potential.32,33Table 4
Amino acid substitutions in penicillin-binding protein 3 of b-lactamase-negative non-
Groupa No. of strains Amino acid substitution
I 1
IIa 1 D350N
IIb 2
5 D350N M377I
4 D350N M377I
1 D350N A437S
1 D350N
IId 1
3
III 1 D350N S357N M377I S385T L389F
a According to the classiﬁcation scheme proposed by Ubukata et al.22 and DabernaWith the exception of serotype a isolates belonging to biotype
II, most other serotypeable strains were of biotype I, which reﬂects
their limited genetic diversity when studied by MLST. In contrast,
seven biotypes were found among the non-typeable strains.
Similarly, among the serotypeable strains, where strains of the
same serotype had most of their alleles identical, many of the non-
typeable strains had most of their alleles different (as many as
seven non-identical alleles). There were eight clonal complexes
found among the non-typeable H. inﬂuenzae, ranging from groups
of two to 13 isolates. The invasive non-typeable isolates from
Manitoba also displayed a high degree of diversity. In this study,
we found 40 unique STs among the 65 non-typeable isolates in
British Columbia, and in Manitoba, we observed 45 unique STs
among 68 isolates.26 There were only 14 STs common to both
provinces. The most common ST in British Columbia was ST-367
(seven isolates), and this ST was not seen in Manitoba; however
related STs (ST-180, ST-3, and ST-14) made up 21% of theManitoba
isolates. ST-14 was most common in Manitoba (eight isolates) and
is different from ST-367 by three alleles.
The serotype and MLST analysis of invasive H. inﬂuenzae
suggests an evolving population of bacteria, possibly as a result oftypeable Haemophilus inﬂuenzae
R517H
N526K
A502V N526K
A502V N506K
A502V N526K V547I
A502V N526K V547I
G490E N526K A530S
I449V N526K
I449V N526K V547I
N526K V547I V562L
t et al.24
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selection from the host. This study based on 98 invasive H.
inﬂuenzae isolates recovered recently in British Columbia conﬁrms
our earlier observation of no detected capsule switching;26
however, non-typeable H. inﬂuenzae has become the predominant
causative agent of invasive H. inﬂuenzae disease. Although the
highly heterogeneous nature of non-typeable H. inﬂuenzae with
many clonal types causing invasive disease may not suggest that
disease is due to evolution of virulent clones, the lack of clinical
information on the patients prevents a more deﬁnite statement on
this issue, especially when four clones were responsible for almost
half of all the invasive cases due to non-typeable strains in British
Columbia.
While none of the 33 invasive encapsulated H. inﬂuenzae in
British Columbia were found to be ampicillin-resistant due to b-
lactamase production, 7.6% of the 53 encapsulated strains in
Manitoba produced b-lactamase and were resistant to ampicil-
lin.26 Similar percentages of non-typeable isolates showing
resistance to ampicillin due to b-lactamase production were
found in both British Columbia and Manitoba. Resistance to
cefaclor and clarithromycinwas rare in both British Columbia and
Manitoba, but resistance to trimethoprim–sulfamethoxazole was
common in both provinces. The most dramatic difference
observed between these two provinces was the much higher
rate of BLNAR genotypes in the invasive non-typeable H.
inﬂuenzae in British Columbia (31%) compared to Manitoba
(13%). Also, thereweremoreb-lactamase producing isolates with
signiﬁcant ftsI gene mutations in British Columbia (4.6%) than in
Manitoba (1.4%). A unique non-typeable isolate was found in
British Columbia that showed resistance to multiple antibiotics,
including chloramphenicol, tetracycline, ampicillin, and trimeth-
oprim–sulfamethoxazole, and had signiﬁcantmutations in the ftsI
gene. The higher number of genotypic BLNAR and BLPACR isolates
in British Columbia may reﬂect an increase in prevalence of such
isolates over time rather than a geographical difference, as the
Manitoba datawere based on isolates collected between 1990 and
2006.34 Regardless of the cause of this difference, the ﬁnding
suggests that continuousmonitoring by laboratory surveillance is
important to track the development of resistance to b-lactam
antibiotics in H. inﬂuenzae.
Besides documenting an evolving H. inﬂuenzae population, the
demographics of patients with invasive H. inﬂuenzae disease has
also changed enormously in the last two decades since the
introduction of Hib vaccines. Instead of being mainly a pediatric
disease, different capsular types and non-encapsulated H. inﬂu-
enzae appear to be causing disease in patients of different age
groups. In 1989, before Hib conjugate vaccines were introduced in
Canada, 24 cases of invasive Hib were reported in the province of
British Columbia. Twenty-one (88%) of these 24 cases were in
children aged 14 years or below and 17 cases (71%) were in
children less than 5 years old. Therewere only three cases in adults
over the age of 25 years (Public Health Agency of Canada, Notiﬁable
Diseases On-line: http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/in-
dex-eng.php). In 2008 and 2009, 75% of the 12 Hib cases were in
adults aged 21 years and above. It appears that serotype a H.
inﬂuenzae has now replaced Hib as the most common cause of
invasive disease in Canadian children aged 2 years or under, with
80% of the cases in British Columbia (this study) and 72% of the
Manitoba cases12 in this age group. More common than serotype a
are non-typeable or non-encapsulated strains as the cause of
invasive disease; and in British Columbia, these strains appear to
affect adults more than children (83% of invasive non-typeable
cases were in those over the age of 18 years). It is not known what
causes patients of a certain age group to be susceptible to certain
strains of invasive H. inﬂuenzae. It could be the immunological
status of the host or perhaps encapsulation and/or other geneticmakeup of the H. inﬂuenzae strains. This is an intriguing question
that is common to many if not all encapsulated invasive bacterial
disease agents and the infectious process; answers to such a
complex question would require more carefully planned studies of
both the pathogen as well as the host.
This was a retrospective laboratory surveillance study, there-
fore there are some limitations to the data observed.While Hib has
been a reportable disease in Canada since 1979, non-Hib cases
have only been included in the revised national notiﬁable disease
list since 2007.35 Therefore, the number of non-Hib cases may
potentially be an underestimate, as not all laboratories may be
familiar with this change and some may not have submitted the
non-Hib isolates for further typing. Also we assumed all patients
were residents of British Columbia and did not consider the
possibility that some patients might have been visitors from other
provinces. We did not look at the rates of disease caused by the
different serotypes or non-typeable strains, and therefore, it was
not possible to determine if there was an overall increase in
invasive H. inﬂuenzae disease or only an increase in the proportion
of non-Hib strains identiﬁed from invasive disease cases. Finally,
we have no historical data on non-Hib disease and it is not possible
to determine if the number of invasive non-Hib disease cases
observed now has changed compared to the number in the past.
However, from a casual comparison of our current data from this
study (with 45–53 cases per year) with the data obtained in 1989
before the Hib conjugate vaccine era (24 cases of Hib), it may be
reasonable to conclude that Hib as a cause of invasive diseases in
children in the past has now been replaced by non-Hib strains
causing invasive disease in adults and serotype a strains causing
disease in young children.
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